CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.

Biotechnology

Health Care

Therapeutics

CeleCor Therapeutics

Robert S. Hillman

Karlien Lubberink

Peter Finn

Oana Cociorva

Marijo Gleeson

Barry S. Coller

The Leadership Team at CeleCor Therapeutics is responsible for setting the strategic direction of the company, overseeing the development and commercialization of their novel small molecule inhibitor, and ensuring financial stability. This team also leads collaborations and partnerships, manages corporate governance, and represents the company to stakeholders.

Leadership Team

Advisory Team

Leadership Team

About

Team members

Other teams at CeleCor Therapeutics

Advisory Team